Kura Oncology Files 8-K on Officer/Director Changes

Ticker: KURA · Form: 8-K · Filed: Jun 6, 2025 · CIK: 1422143

Kura Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyKura Oncology, INC. (KURA)
Form Type8-K
Filed DateJun 6, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, governance, officer-appointment, director-election

Related Tickers: KURA

TL;DR

Kura Oncology's leadership team is changing, with new officers and directors appointed.

AI Summary

Kura Oncology, Inc. filed an 8-K on June 6, 2025, reporting on several key events that occurred on June 5, 2025. These include the departure of directors or certain officers, the election of directors, the appointment of certain officers, and details regarding compensatory arrangements for certain officers. The filing also covers the submission of matters to a vote of security holders and includes financial statements and exhibits.

Why It Matters

This filing indicates significant changes in Kura Oncology's leadership and governance structure, which could impact the company's strategic direction and operational execution.

Risk Assessment

Risk Level: medium — Changes in key personnel and board composition can signal strategic shifts or internal challenges, warranting closer observation.

Key Players & Entities

FAQ

Who are the specific directors or officers departing from Kura Oncology?

The filing indicates the departure of directors or certain officers but does not name them in the provided text.

Who has been elected as new directors for Kura Oncology?

The filing states the election of directors occurred but does not specify the names of the newly elected individuals.

Which officers have been appointed to new positions within Kura Oncology?

The filing reports the appointment of certain officers but does not provide their names or specific roles.

What specific matters were submitted to a vote of Kura Oncology's security holders?

The filing indicates that matters were submitted to a vote of security holders, but the details of these matters are not included in the provided text.

Are there any details on the compensatory arrangements for the officers mentioned?

The filing notes that compensatory arrangements of certain officers are covered, but specific details are not provided in the excerpt.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 6, 2025 regarding Kura Oncology, Inc. (KURA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing